Published in Mol Cancer Ther on February 18, 2015
CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition. Am J Clin Oncol (2016) 1.39
Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patients. Virchows Arch (2016) 1.10
Imaging, Biodistribution, and Dosimetry of Radionuclide-Labeled PD-L1 Antibody in an Immunocompetent Mouse Model of Breast Cancer. Cancer Res (2015) 1.08
Expression of programmed death ligand-1 on tumor cells varies pre and post chemotherapy in non-small cell lung cancer. Sci Rep (2016) 1.03
Programmed death-ligand 1 overexpression is a prognostic marker for aggressive papillary thyroid cancer and its variants. Oncotarget (2016) 0.92
CD274/PD-L1 gene amplification and PD-L1 protein expression are common events in squamous cell carcinoma of the oral cavity. Oncotarget (2016) 0.89
Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma. J Clin Invest (2016) 0.89
Biomarker development in the precision medicine era: lung cancer as a case study. Nat Rev Cancer (2016) 0.89
Prognostic effect of different PD-L1 expression patterns in squamous cell carcinoma and adenocarcinoma of the cervix. Mod Pathol (2016) 0.86
Prognostic impact of programed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer. Mol Cancer (2016) 0.85
PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas. Nat Rev Clin Oncol (2016) 0.85
Phase I study with ONCOS-102 for the treatment of solid tumors - an evaluation of clinical response and exploratory analyses of immune markers. J Immunother Cancer (2016) 0.85
Advances in immunotherapy for melanoma. BMC Med (2016) 0.83
Inhibitory receptors as targets for cancer immunotherapy. Eur J Immunol (2015) 0.83
PD-L1 Detection in Tumors Using [(64)Cu]Atezolizumab with PET. Bioconjug Chem (2016) 0.83
Gene-expression profiling to predict responsiveness to immunotherapy. Cancer Gene Ther (2016) 0.83
PD-L1 Expression and Survival among Patients with Advanced Non-Small Cell Lung Cancer Treated with Chemotherapy. Transl Oncol (2016) 0.82
Targeted therapy for advanced gastric cancer: A review of current status and future prospects. World J Gastrointest Oncol (2015) 0.82
Integrative clinical genomics of metastatic cancer. Nature (2017) 0.82
Targeting neoantigens to augment antitumour immunity. Nat Rev Cancer (2017) 0.81
Increased expression of programmed death ligand 1 (PD-L1) in human pituitary tumors. Oncotarget (2016) 0.81
Imaging Biomarkers in Immunotherapy. Biomark Cancer (2016) 0.81
Nivolumab in combination with ipilimumab for the treatment of melanoma. Expert Rev Anticancer Ther (2015) 0.81
The potential of tumor-derived exosomes for noninvasive cancer monitoring. Expert Rev Mol Diagn (2015) 0.81
Expression of PD-L1 in triple-negative breast cancer based on different immunohistochemical antibodies. J Transl Med (2016) 0.81
Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy. J Immunother Cancer (2017) 0.80
Epithelial-to-Mesenchymal Transition in the Pathogenesis and Therapy of Head and Neck Cancer. Cancers (Basel) (2017) 0.80
Immunotherapy of Malignant Tumors in the Brain: How Different from Other Sites? Front Oncol (2016) 0.80
The prevalence and clinicopathological features of programmed death-ligand 1 (PD-L1) expression: a pooled analysis of literatures. Oncotarget (2016) 0.80
Monitoring PD-L1 positive circulating tumor cells in non-small cell lung cancer patients treated with the PD-1 inhibitor Nivolumab. Sci Rep (2016) 0.80
Intra-tumoral heterogeneity in the expression of programmed-death (PD) ligands in isogeneic primary and metastatic lung cancer: Implications for immunotherapy. Oncoimmunology (2016) 0.80
(89)Zr-labeled nivolumab for imaging of T-cell infiltration in a humanized murine model of lung cancer. Eur J Nucl Med Mol Imaging (2017) 0.80
PD-L1 expression in non-small cell lung cancer: Correlations with genetic alterations. Oncoimmunology (2016) 0.80
Next generation predictive biomarkers for immune checkpoint inhibition. Cancer Metastasis Rev (2016) 0.80
Practical ImmunoPET radiotracer design considerations for human immune checkpoint imaging. J Nucl Med (2016) 0.80
Robust detection of immune transcripts in FFPE samples using targeted RNA sequencing. Oncotarget (2016) 0.79
Programmed death-ligand 1 (PD-L1) characterization of circulating tumor cells (CTCs) in muscle invasive and metastatic bladder cancer patients. BMC Cancer (2016) 0.79
Metastatic basal cell carcinoma with amplification of PD-L1: exceptional response to anti-PD1 therapy. NPJ Genom Med (2016) 0.78
The Future of Immunotherapy in the Treatment of Small Cell Lung Cancer. Oncologist (2016) 0.78
Immune Checkpoint Modulation in Colorectal Cancer: What's New and What to Expect. J Immunol Res (2015) 0.78
Genomic portfolio of Merkel cell carcinoma as determined by comprehensive genomic profiling: implications for targeted therapeutics. Oncotarget (2016) 0.78
Checkpoint Proteins in Pediatric Brain and Extracranial Solid Tumors: Opportunities for Immunotherapy. Clin Cancer Res (2016) 0.77
Moving towards a customized approach for drug development: lessons from clinical trials with immune checkpoint inhibitors in lung cancer. Transl Lung Cancer Res (2015) 0.77
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response. Biomark Res (2017) 0.77
Molecular inimitability amongst tumors: implications for precision cancer medicine in the age of personalized oncology. Oncotarget (2015) 0.77
Potential role of immunotherapy in advanced non-small-cell lung cancer. Onco Targets Ther (2016) 0.77
SCHLAFEN 5 expression correlates with intestinal metaplasia that progresses to gastric cancer. J Gastroenterol (2016) 0.77
Integration of genomics and histology revises diagnosis and enables effective therapy of refractory cancer of unknown primary with PDL1 amplification. Cold Spring Harb Mol Case Stud (2016) 0.77
Systems immune monitoring in cancer therapy. Eur J Cancer (2016) 0.77
5-Fluorouracil upregulates cell surface B7-H1 (PD-L1) expression in gastrointestinal cancers. J Immunother Cancer (2016) 0.76
Using MRI to evaluate and predict therapeutic success from depot-based cancer vaccines. Mol Ther Methods Clin Dev (2015) 0.76
Adenoviral Delivery of Tumor Necrosis Factor-α and Interleukin-2 Enables Successful Adoptive Cell Therapy of Immunosuppressive Melanoma. Mol Ther (2016) 0.76
Mismatch repair deficiency associated with complete remission to combination programmed cell death ligand immune therapy in a patient with sporadic urothelial carcinoma: immunotheranostic considerations. J Immunother Cancer (2015) 0.76
Pembrolizumab for the treatment of PD-L1 positive advanced or metastatic non-small cell lung cancer. Expert Rev Anticancer Ther (2016) 0.76
A phase II study of belinostat (PXD101) in relapsed and refractory aggressive B-cell lymphomas: SWOG S0520. Leuk Lymphoma (2016) 0.76
Molecular Imaging of Immunotherapy Targets in Cancer. J Nucl Med (2016) 0.76
PD-L1 (CD274) copy number gain, expression, and immune cell infiltration as candidate predictors for response to immune checkpoint inhibitors in soft-tissue sarcoma. Oncoimmunology (2017) 0.76
Genomic landscape of DNA repair genes in cancer. Oncotarget (2016) 0.76
Hyper-progressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate. Clin Cancer Res (2017) 0.76
PD-L1 Expression in Human Placentas and Gestational Trophoblastic Diseases. Int J Gynecol Pathol (2017) 0.76
Precision Medicine for Molecularly Targeted Agents and Immunotherapies in Early-Phase Clinical Trials. Transl Oncogenomics (2015) 0.75
Effect of cryopreservation on delineation of immune cell subpopulations in tumor specimens as determinated by multiparametric single cell mass cytometry analysis. BMC Immunol (2017) 0.75
Interplay between Immune Checkpoint Proteins and Cellular Metabolism. Cancer Res (2017) 0.75
PD-L1 Status in Refractory Lymphomas. PLoS One (2016) 0.75
Establishing a complementary diagnostic for anti-PD-1 immune checkpoint inhibitor therapy. Ann Oncol (2016) 0.75
Omics approaches to individual variation: modeling networks and the virtual patient. Dialogues Clin Neurosci (2016) 0.75
Tumor-Associated Lymphatic Vessels Upregulate PDL1 to Inhibit T-Cell Activation. Front Immunol (2017) 0.75
Expression of PD-L1 and presence of CD8-positive T cells in pre-treatment specimens of locally advanced cervical cancer. Mod Pathol (2017) 0.75
High expression of PD-1 ligands is associated with kataegis mutational signature and APOBEC3 alterations. Oncoimmunology (2017) 0.75
Strengthening the case that elevated levels of programmed death ligand 1 predict poor prognosis in hepatocellular carcinoma patients. J Hepatocell Carcinoma (2016) 0.75
The prognostic role of immune checkpoint markers programmed cell death protein 1 (PD-1) and programmed death ligand 1 (PD-L1) in a large, multicenter prostate cancer cohort. Oncotarget (2017) 0.75
Using lymph node swelling as a potential biomarker for successful vaccination. Oncotarget (2016) 0.75
A blockade of PD-L1 produced antitumor and antimetastatic effects in an orthotopic mouse pancreatic cancer model via the PI3K/Akt/mTOR signaling pathway. Onco Targets Ther (2017) 0.75
Catching up with solid tumor oncology: what is the evidence for a prognostic role of programmed cell death-ligand 1/programmed cell death-1 expression in B-cell lymphomas? Haematologica (2016) 0.75
Predictive and Prognostic Molecular Biomarkers for Response to Neoadjuvant Chemoradiation in Rectal Cancer. Int J Mol Sci (2017) 0.75
National Comprehensive Cancer Network Recommendations on Molecular Profiling of Advanced Bladder Cancer. J Clin Oncol (2016) 0.75
Advancing Immune and Cell-Based Therapies Through Imaging. Mol Imaging Biol (2017) 0.75
Predictive biomarkers of immunotherapy for non-small cell lung cancer: results from an Experts Panel Meeting of the Italian Association of Thoracic Oncology. Transl Lung Cancer Res (2017) 0.75
Expression of programmed death ligand-1 predicts poor outcome in nasopharyngeal carcinoma. Mol Clin Oncol (2017) 0.75
Impact of the Tumor Microenvironment on Tumor-Infiltrating Lymphocytes: Focus on Breast Cancer. Breast Cancer (Auckl) (2017) 0.75
PD-1 mRNA expression in peripheral blood cells and its modulation characteristics in cancer patients. Oncotarget (2017) 0.75
Immunotherapy in Gastrointestinal Cancers. Biomed Res Int (2017) 0.75
Interleukin-17A Promotes Lung Tumor Progression Through Neutrophil Attraction to Tumor Sites and Mediating Resistance to PD-1 Blockade. J Thorac Oncol (2017) 0.75
A regulatory role for the co-chaperone FKBP51s in PD-L1 expression in glioma. Oncotarget (2017) 0.75
TCR Repertoire Intratumor Heterogeneity in Localized Lung Adenocarcinomas: an Association with Predicted Neoantigen Heterogeneity and Postsurgical Recurrence. Cancer Discov (2017) 0.75
Overexpression of PD-L2 is associated with shorter relapse-free survival in patients with malignant salivary gland tumors. Onco Targets Ther (2017) 0.75
Clinical implications of the novel cytokine IL-38 expressed in lung adenocarcinoma: Possible association with PD-L1 expression. PLoS One (2017) 0.75
Current state of immunotherapy for non-small cell lung cancer. Transl Lung Cancer Res (2017) 0.75
Dosing immunotherapy combinations: Analysis of 3,526 patients for toxicity and response patterns. Oncoimmunology (2017) 0.75
PD-L1/PD-1 expression and tumor-infiltrating lymphocytes in conjunctival melanoma. Oncotarget (2017) 0.75